



## LUNG CANCER SCREENING

**Sazdanic-Velikić Danica**

*Clinic for pulmonary oncology, Institute for lung diseases of Vojvodina, Sremska Kamenica, School of medicine, University of Novi Sad*

### Abstract:

Patients with lung cancer are mostly diagnosed when they present with symptoms, they have advanced stage disease and curative treatment is not possible. Detecting the disease and initiating treatment at an early stage are important for improving survival. Low-dose computed tomography (LDCT) is strategy for lung cancer detection that has demonstrated promise in purpose to identify the presence of lung cancer in an early stage when individuals does not demonstrate any symptoms and curative treatment is feasible. Based on the results of the National Lung Screening Trial (NLST), NELSON trial, the US Preventive Services Task Force and NCCN guideline recommend annual lung cancer screening with LDCT. According to the leading guidelines annual screening for lung cancer with low-dose computed tomography (LDCT) is recommended in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Concerns associated with LDCT screening include: radiation exposure, management of false negative and false-positive results, incidental findings, overdiagnosis. Patients with several comorbid conditions may be at greater risk.

### Biography:

Danica Sazdanic-Velikić, MD, PhD was a pneumophysiologist-oncologist and also working as a Teaching assistant (PhD) at Department for Geriatrics, University of Novi Sad, Faculty of medicine. He was a Chief of Department for patients treated with radiotherapy and Clinic for pulmonary oncology at Institute for pulmonary diseases of Vojvodina, Sremska Kamenica, Serbia.



### Recent Publications:

1. P2.03a-042 Comorbidity as a Prognostic Factor in Elderly Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy January 2017 *Journal of Thoracic Oncology* 12(1):S914 DOI: 10.1016/j.jtho.2016.11.1251
2. PUB117 Beta Estrogen Receptor as Potential Prognostic Factor in Lung Adenocarcinoma, January 2017 *Journal of Thoracic Oncology* 12(1):S1515-S1516, DOI: 10.1016/j.jtho.2016.11.2088
3. Cardiotoxic effects of gemcitabine/cisplatin vs paclitaxel/carboplatin first-line chemotherapy in patients with advanced non-small cell lung cancer October 2016 *Annals of Oncology* 27(suppl\_6) Follow journal, DOI: 10.1093/annonc/mdw382.13

Webinar on Pulmonology | October 11th, 2020 | UAE, Dubai

Citation: Sazdanic-Velikić Danica, Lung Cancer Screening, Pulmonology 2020, October 11th, 2020, UAE, Dubai